drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Subcutaneous BCMA/CD3 bispecific T-cell engager (BiTE) antibody that binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells to redirect T-cell cytotoxicity and cytokine release against BCMA-positive plasma cells; uses step-up priming followed by weekly/biweekly dosing to prevent progression of high-risk smoldering multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Bispecific T-cell engager antibody that binds BCMA on malignant plasma cells and CD3 on T cells to form an immunologic synapse, activating T-cell cytotoxicity and cytokine release to kill BCMA-positive plasma cells.
drug_name
CM336
nct_id_drug_ref
NCT06745687